Class Action

Combivent Respimat Asthma Inhalers

Class Action

Combivent Respimat Asthma Inhalers

In May 2019, a class-action lawsuit was filed against Boehringer Ingelheim Pharmaceuticals for allegedly deceptively marketing that the Combivent Respimat asthma inhaler will provide 120 doses when, according to plaintiffs, the inhaler contains far fewer dosages, sometimes less than half the advertised amount. (Ignacuinos et al v. Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-672, D. Conn.)


The Latest

Filters

Fisher Investments

Ad Alert

Fisher Investments

Unearthing the fees that Fisher charges but doesn’t disclose in some of its TV ads.


Show More